Be assured that this conclusion from Dr. Sabbagh, head of the Anavex Scientific Advisory Board, will significantly reduce or eliminate any chance of buyout interest from BP, especially for prophylactic use!
“A crucial consideration is that, unlike the other therapeutics mentioned in this commentary, S1R activation covers a broad range of disease mechanisms related to lysosomal misfunction and subsequent degradation of misfolded proteins and has high potential for adverse effects due to the numerous functions regulated by S1R, such as inflammation, mitochondrial function, and neurotransmission.For example, blarcamesine is known to activate the muscarinic M1 and NMDA receptors, with the latter being implicated in brain hyperactivity. Thus, further research is needed to test this
molecule for the slowing of AD progression.
In addition, this type of drug will likely necessitate a shuttle carrier for brain delivery in order to prevent peripheral off-
target actions. This compound is likely
going to require a longer period of clinical
testing before requests for commercialization
can be filed.”
Despite Mayo’s efforts with Dr. Sabbagh, Cell have not retracted the damming conclusions above.
The longer we wait, the sooner we will get rich!
Market Data 
Markets 
